Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Popular weight-loss medications — including semaglutide, tirzepatide, and liraglutide — don't appear to raise the risk of respiratory side effects compared to placebo, according to a sweeping new meta-analysis. Researchers reviewed 123 studies and found no significant increase in respiratory adverse events across the board. However, evidence specifically in patients with asthma remains thin, leaving an important gap for future research.
Good news for patients on popular weight-loss drugs: a large systematic review and meta-analysis published in the Annals of the American Thoracic Society found that liraglutide, semaglutide, tirzepatide, and naltrexone-bupropion do not increase the risk of respiratory adverse events compared to placebo. Researchers from Johns Hopkins Bloomberg School of Public Health analyzed 123 studies — including 116 randomized controlled trials — covering a range of weight-loss medications and respiratory outcomes.
Across GLP-1 and dual GLP-1/GIP receptor agonists, there were no significant differences in rates of lower respiratory tract infections, cough, or most upper respiratory tract infections versus placebo. Two minor exceptions — sinusitis and rhinitis — showed small but statistically significant differences, though researchers cautioned these may reflect chance findings given the large number of outcomes analyzed.
By the Numbers:
Why it matters: With obesity and asthma frequently co-occurring, clinicians often weigh the respiratory safety of weight-loss drugs carefully. These findings offer reassurance — but also highlight a critical evidence gap: respiratory outcomes in asthma patients are rarely reported in weight-loss trials, and more targeted research is urgently needed.
